Prof. Dr. Murat Binbay'ın akademik çalışmaları — tam metinleri PDF olarak indirebilirsiniz.
In the JCOG1403 phase 3 trial, a single dose of intravesical pirarubicin given within 24 hours of radical nephroureterectomy raised 3-year relapse-free survival from 47% to 60% (Lancet Oncology, 2026).
In the PROTEUS trial, perioperative apalutamide plus ADT reduced the risk of metastasis or death by 20% while increasing the pathological complete response rate ninefold (NEJM, 2026).
In the FDA-approved POTOMAC trial, durvalumab plus BCG reduced DFS risk by 32% in BCG-naive high-risk NMIBC; the cystectomy rate fell from 25% to 8%.
In the ENVISION trial, 72.2% of LG-IR-NMIBC patients who achieved a complete response with UGN-102 at month 3 remained event-free at 24 months, demonstrating durability of response.
In the phase 3 PrTK03 trial, CAN-2409 plus valaciclovir added to EBRT reduced the risk of recurrence or death in prostate cancer by 30% (HR 0.70; p=0.016).
In the phase III KEYNOTE-B15 trial, EV plus pembrolizumab was superior to standard chemotherapy in MIBC with a 47% risk reduction in EFS, a 35% reduction in OS and a 55.8% pCR rate.
Based on IMvigor011, the FDA approved adjuvant atezolizumab in ctDNA MRD-positive MIBC patients, extending DFS from 4.8 to 9.9 months and OS from 21.1 to 32.8 months.
An analysis of 3,477 patients from HEAT and ICE reported a 10-year prostate cancer-specific mortality of 0.13% and a metastasis incidence of 3.3% with focal HIFU/cryotherapy.
The FDA has approved tebipenem pivoxil, the first oral carbapenem for the treatment of complicated UTI. PIVOT-PO phase 3: 1,690 patients, non-inferiority to IV imipenem demonstrated.